Publicaciones en las que colabora con Ángela Peñalva Maqueda (8)

1998

  1. Acute changes in free-fatty acids (FFA) do not alter serum leptin levels

    Journal of Endocrinological Investigation, Vol. 21, Núm. 8, pp. 526-530

  2. Effect of acute pharmacological reduction of plasma free fatty acids on growth hormone (GH) releasing hormone-induced GH secretion in obese adults with and without hypopituitarism

    Journal of Clinical Endocrinology and Metabolism, Vol. 83, Núm. 12, pp. 4350-4354

  3. La administracion por via oral de dosis bajas de growth hormone releasing hexapeptide-6-mas piridostigmina es un estimulo adecuado de la secrecion de GH

    Endocrinologia, Vol. 45, Núm. 10, pp. 341-344

1996

  1. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli

    Journal of Clinical Endocrinology and Metabolism, Vol. 81, Núm. 3, pp. 909-913

  2. Growth hormone releasing hexapeptide-6 (GHRP-6) in test in the diagnosis of GH-deficiency

    Journal of Pediatric Endocrinology and Metabolism

  3. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression

    Journal of Clinical Endocrinology and Metabolism, Vol. 81, Núm. 3, pp. 914-918

1995

  1. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection

    Journal of Clinical Endocrinology and Metabolism, Vol. 80, Núm. 11, pp. 3180-3184

  2. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects

    Metabolism, Vol. 44, Núm. 6, pp. 745-748